Technology area: Biotechnology & Pharmaceuticals
20 pending office actions • 17 art units • 18 examiners • 0 of 20 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
The University of Toledo has 20 pending office actions in Biotechnology & Pharmaceuticals. The workload spans 18 distinct examiners and 17 distinct art units, reflecting a broad and distributed prosecution portfolio rather than a single examination channel.
WESTON, ALYSSA G is the busiest examiner, with 2 pending matters. The limited concentration with that examiner means counsel should combine portfolio-level tracking with matter-specific response planning across the other assignments.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (15%) |
| §103 only | 5 (25%) |
| §112 only | 2 (10%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 1 (5%) |
| Multi-statute (no §101) | 8 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 2 | 59.5% | +49.0% |
| HUYNH, PHUONG N | 2 | 65.8% | +53.6% |
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| HOWELL, GWYNNETH LINNEA | 1 | 43.2% | +79.8% |
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
| MALEVIC, DJURA | 1 | 78.1% | +10.1% |
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18353183 | Synergistic Inhibition of eIF5A and Notch Signaling | HUYNH, PHUONG N | 28d |
| 17859260 | THREE-WAY UROLOGY CATHETER STOPCOCK AND UROLOGY CATHETER STOPCOCK ASSEMBLY | PATEL, SHEFALI DILIP | 54d |
| 18417805 | COMPOUNDS HAVING SELECTIVE INACTIVATION ACTIVITY | WAX, ROBERT A | 70d |
| 18862993 | Antimicrobial Compositions and Uses for Treatment of Clostridioides difficile, Mycobacterium tuberculosis, and Enterococcus faecalis Infection | HASTINGS, ALISON AZAR | — |
| 18674217 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | HUYNH, PHUONG N | — |
| 18640844 | PRESSURE ULCER BOOT | HOWELL, GWYNNETH LINNEA | — |
| 18585551 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | SCHMIDT, IZABELA MARIA | — |
| 18506571 | MONOCLONAL IGM ANTIBODIES FROM ENTIRELY CARBOHYDRATE CONSTRUCTS | LI, RUIXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18353183 | Synergistic Inhibition of eIF5A and Notch Signaling | HUYNH, PHUONG N | 28d |
| 18971862 | IMMUNOSUPPRESSIVE ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR TREG CELLS FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE AND ALLOIMMUNE DISORDERS | WESTON, ALYSSA G | — |
| 18862993 | Antimicrobial Compositions and Uses for Treatment of Clostridioides difficile, Mycobacterium tuberculosis, and Enterococcus faecalis Infection | HASTINGS, ALISON AZAR | — |
| 18931782 | Immunosuppressive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune and Alloimmune Disorders | WESTON, ALYSSA G | — |
| 18674217 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | HUYNH, PHUONG N | — |
| 18670112 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | JACKSON-TONGUE, LAKIA J | — |
| 18640844 | PRESSURE ULCER BOOT | HOWELL, GWYNNETH LINNEA | — |
| 18585551 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | SCHMIDT, IZABELA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1641 | 2 |
| 1675 | 2 |
| 1627 | 1 |
| 1645 | 1 |
| 3785 | 1 |
| 1621 | 1 |
| 2884 | 1 |
| 1615 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18971862 | IMMUNOSUPPRESSIVE ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR TREG CELLS FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE AND ALLOIMMUNE DISORDERS | WESTON, ALYSSA G | 1633 | §102§103§112DP | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18862993 | Antimicrobial Compositions and Uses for Treatment of Clostridioides difficile, Mycobacterium tuberculosis, and Enterococcus faecalis Infection | HASTINGS, ALISON AZAR | 1627 | §101§102§103§112DP | Non-Final OA | — | Pending | Nov 05, 2024 |
| 18931782 | Immunosuppressive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune and Alloimmune Disorders | WESTON, ALYSSA G | 1633 | DP | Non-Final OA | — | Pending | Oct 30, 2024 |
| 18674217 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | HUYNH, PHUONG N | 1641 | §101§103§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18670112 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | JACKSON-TONGUE, LAKIA J | 1645 | §112Other | Non-Final OA | — | Pending | May 21, 2024 |
| 18640844 | PRESSURE ULCER BOOT | HOWELL, GWYNNETH LINNEA | 3785 | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18585551 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | SCHMIDT, IZABELA MARIA | 1621 | §102§103 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18580987 | SOLID PHANTOM DEVICE FOR BEAM SCANNING | MALEVIC, DJURA | 2884 | §103 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18417805 | COMPOUNDS HAVING SELECTIVE INACTIVATION ACTIVITY | WAX, ROBERT A | 1615 | §103§112 | Non-Final OA | 70d | Pending | Jan 19, 2024 |
| 18506571 | MONOCLONAL IGM ANTIBODIES FROM ENTIRELY CARBOHYDRATE CONSTRUCTS | LI, RUIXIANG | 1674 | §102§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18557651 | METHODS OF TREATING CANCER AND ISCHEMIA DISEASES BY INHIBITION AND INTERVENTION OF ATR PROLYL ISOMERIZATION | SEAMAN, D MARGARET M | 1625 | §102§103 | Final Rejection | — | Pending | Oct 27, 2023 |
| 18353183 | Synergistic Inhibition of eIF5A and Notch Signaling | HUYNH, PHUONG N | 1641 | §103§112Other | Final Rejection | 28d | Pending | Jul 17, 2023 |
| 18038053 | QUANTIFICATION OF SPERM CENTRIOLE QUALITY | BORGEEST, CHRISTINA M | 1675 | §101§103 | Final Rejection | — | Pending | May 22, 2023 |
| 18314240 | OSTEOANABOLISM BY 14-3-3ZETA | DONOGHUE, BRITTNEY ERIN | 1675 | §112 | Final Rejection | — | Pending | May 09, 2023 |
| 18101812 | Aspiration Catheter with an Adjustable Tip for the Intracranial Circulation | SMITH, PETER DANIEL | 3781 | §102§103 | Final Rejection | — | Pending | Jan 26, 2023 |
| 18093057 | ANTIMICROBIAL FILTRATION | HORGER, KIM S. | 1784 | §103 | Final Rejection | 46d overdue | Pending | Jan 04, 2023 |
| 17859260 | THREE-WAY UROLOGY CATHETER STOPCOCK AND UROLOGY CATHETER STOPCOCK ASSEMBLY | PATEL, SHEFALI DILIP | 3783 | §103§112 | Non-Final OA | 54d | Pending | Jul 07, 2022 |
| 17775932 | Methods and Kits using Internal Standards to Control for Complexity of Next Generation Sequencing(NGS) Libraries | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103 | Non-Final OA | 36d overdue | Pending | May 11, 2022 |
| 17737325 | Emulsion Formation Assisted by Corona Discharge and Electrohydrodynamic Pumping | BRAZIN, JACQUELINE | 1798 | §103 | Final Rejection | 27d | Pending | May 05, 2022 |
| 17178455 | SUPER SENSITIVE SENSOR FOR THE DETECTION OF HYDROXYL FREE RADICALS WITH SCAVENGING PROPERTIES | SUN, CAITLYN MINGYUN | 1795 | §103 | Non-Final OA | 1d overdue | Pending | Feb 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe University of Toledo has 20 pending office actions as of October 2026, spread across 17 art units and 18 examiners.
Alyssa G Weston has the most, with 2 of The University of Toledo's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
